Our psychopharmacological studies all involve psychiatric patients and range from Phase Ib till Phase IV trials. Since 2012, we have been involved in 14 trials (2016). Many of our studies have a strong focus on biomarker discovery.
This pie chart represents the population size of our current and closed studies. Depending on the protocol and the study phase, most of the studies have a population size of 31-100 participants.
Our psychopharmacological trials are strongly focused on mood disorders, such as recurrent depression (MDD), and psychotic disorders, such as schizophrenia. Other neuropsychiatric and some neurological disorders (sleep disorders and epilepsy) have also been studied.